Home  »  Industry   »  Meeting and exceeding analyst predictions: Vallon ...

Meeting and exceeding analyst predictions: Vallon Pharmaceuticals Inc. (VLON)

At the end of the latest market close, Vallon Pharmaceuticals Inc. (VLON) was valued at $0.33. In that particular session, Stock kicked-off at the price of $0.333 while reaching the peak value of $0.3945 and lowest value recorded on the day was $0.285. The stock current value is $0.36.Recently in News on July 28, 2022, Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update. Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update. You can read further details here

Vallon Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.8000 on 01/06/22, with the lowest value was $0.2850 for the same time period, recorded on 09/22/22.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Vallon Pharmaceuticals Inc. (VLON) full year performance was -94.89%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Vallon Pharmaceuticals Inc. shares are logging -95.77% during the 52-week period from high price, and 8.28% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.33 and $8.54.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1138981 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vallon Pharmaceuticals Inc. (VLON) recorded performance in the market was -93.96%, having the revenues showcasing -24.77% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.85M, as it employees total of 3 workers.

Specialists analysis on Vallon Pharmaceuticals Inc. (VLON)

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.5474, with a change in the price was noted -0.88. In a similar fashion, Vallon Pharmaceuticals Inc. posted a movement of -70.88% for the period of last 100 days, recording 432,887 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for VLON is recording 0.03 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Trends and Technical analysis: Vallon Pharmaceuticals Inc. (VLON)

Raw Stochastic average of Vallon Pharmaceuticals Inc. in the period of last 50 days is set at 16.37%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 39.23%. In the last 20 days, the company’s Stochastic %K was 13.46% and its Stochastic %D was recorded 10.19%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -93.96%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -82.97%, alongside a downfall of -94.89% for the period of the last 12 months. The shares increased approximately by -8.02% in the 7-day charts and went up by -16.99% in the period of the last 30 days. Common stock shares were lifted by -24.77% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts